OncoResponse Overview
- Founded
-
2015

- Status
-
Private
- Employees
-
35

- Latest Deal Type
-
Debt
- Latest Deal Amount
-
$50M
- Investors
-
24
OncoResponse General Information
Description
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer patients who have responded exceptionally well to Checkpoint Inhibition (CPI). The company leverages a proprietary B-cell technology platform to develop cancer immunotherapies and therapeutic antibodies against immuno-oncology targets by interrogating the human immune system, enabling doctors and patients to optimally combat cancer.
Contact Information
Website
www.oncoresponse.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
- 1124 Columbia Street
- Suite 300
- Seattle, WA 98104
- United States
+1 (206) 000-0000
OncoResponse Timeline
OncoResponse Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Debt - General | 08-Feb-2022 | $50M | 00000 | Completed | Clinical Trials - Phase 1 | |
4. Later Stage VC (Series C) | 25-Mar-2021 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
3. Early Stage VC (Series B) | 14-Jun-2019 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
2. Early Stage VC (Series A) | 23-Mar-2017 | $29.5M | $29.5M | 0000 | Completed | Pre-Clinical Trials |
1. Joint Venture | 18-Aug-2015 | Completed | Startup |
OncoResponse Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series C | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.00 |
Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 29,499,000 | $0.001000 | $0.06 | $1 | $1 | 1x | $1 | 20.32% |
OncoResponse Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of therapeutic antibodies designed for the treatment of cancer by probing the adaptive immune system of cancer
Drug Discovery
Seattle, WA
35
As of 2023
00000
000000000
00000
OncoResponse Competitors (122)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Aura Biosciences | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
000000000 00000000 | Venture Capital-Backed | Austin, TX | 00 | 00000 | 00000000000 | 00000 |
000000-000 0000000 | Venture Capital-Backed | Palo Alto, CA | 00 | 00000 | 00000000000 | 00000 |
00000000 000000000 | Venture Capital-Backed | Pasadena, CA | 0 | 00.000 | 000000000 | 00.000 |
000000 00000000000 | Venture Capital-Backed | Plymouth Meeting, PA | 00 | 000.00 | 00000000000 | 000.00 |
OncoResponse Patents
OncoResponse Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210047424-A1 | Immunomodulatory antibodies and methods of use thereof | Active | 19-Jul-2019 | 00000000000 | |
US-11034770-B2 | Immunomodulatory antibodies and methods of use thereof | Active | 19-Jul-2019 | 00000000000 | |
US-20220289861-A1 | Immunomodulatory antibodies and methods of use thereof | Pending | 19-Jul-2019 | 00000000000 | |
US-20210253733-A1 | Immunomodulatory antibodies and methods of use thereof | Pending | 19-Jul-2019 | 00000000000 | |
AU-2020315878-A1 | Immunomodulatory antibodies and methods of use thereof | Pending | 19-Jul-2019 | C07K16/2896 |
OncoResponse Executive Team (7)
OncoResponse Board Members (14)
Name | Representing | Role | Since |
---|---|---|---|
Clifford Stocks | OncoResponse | Co-Founder, Chief Executive Officer & Board Member | 000 0000 |
Daguang Wang Ph.D | Yonjin Venture | Board Member | 000 0000 |
David DeNardo Ph.D | OncoResponse | scientific advisor | 000 0000 |
John Mckearn Ph.D | RiverVest Venture Partners | Board Member | 000 0000 |
Miriam Merad Ph.D | OncoResponse | scientific advisor | 000 0000 |
OncoResponse Signals
OncoResponse Investors (24)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Bering Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
InterVest | Venture Capital | Minority | 000 0000 | 000000 0 | |
Magnetar Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Reimagined Ventures | Family Office | Minority | 000 0000 | 000000 0 | |
Yonjin Venture | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
OncoResponse Acquisitions (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 0000 | 07-Nov-2017 | 0000000000 | Biotechnology | 00000000 |